Getting FDA clearance used to be the finish line. Now it's just the starting gate. Cindy Grabowski has watched medtech acquisition timelines stretch from three years to eight-plus years across her 30-year career, and she knows exactly why the rules changed. In this episode, she breaks down the 2012 turning point when big medtech companies shifted their acquisition criteria from regulatory approval to predictable payment. You'll learn why reimbursement strategy must start on day one, how to design clinical trials that work globally, and what the five-publication requirement really means for Category 1 CPT codes. If you're a founder who thinks regulatory approval will get you acquired, this conversation will change your strategy.

Timestamps:

00:00 - Introduction: The evolution of medtech acquisitions

02:00 - The 2004 shift: When big medtech changed their acquisition model

05:00 - The 2012 turning point: Predictable payment becomes the new bar

08:00 - Why FDA clearance is no longer the finish line

11:00 - Designing clinical studies with global data in mind

16:00 - How AI can accelerate protocol development

19:00 - AMA requirements for reimbursement and the five-publication rule

24:00 - The trap of "we only need enough data for regulatory approval"

29:00 - Four critical roles every founder must align from day one

33:00 - Mind Grove: Building cross-functional training for medtech professionals

36:00 - Rapid fire questions

40:00 - Where to connect with Cindy

Follow Melita and Cindy:

Connect with Melita: 

LinkedIn: https://www.linkedin.com/in/melitaball/

Website: https://www.mbcaconsulting.com/

Connect with Cindy: 

LinkedIn: https://www.linkedin.com/in/cindy-grabowski/

Website: https://mindgrove.com/